

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



January 8, 2026

To Whom It May Concern:

Company Name: FUJI Co., LTD.
Name of representative: Hiroshi Yamaguchi, Representative Director and President
(Securities Code: 8278 TSE Prime Market)
Contact: Yasuhiko Toyoda, Director, and Senior Executive Officer in Charge of Planning and Development
(TEL +81-82-535-8516)

(Disclosure Update) Notice Regarding Share Transfer of Equity Method Affiliate and Recording of Extraordinary Gains

As disclosed in the “Notice Regarding Changes in Equity Method Affiliates (Share Transfer) and Recording of Extraordinary Gains” dated November 20, 2025, FUJI Co., LTD. (“FUJI”) has transferred all of its shares (“Share Transfer”) of Lady Drug Store Co., Ltd., which was an equity-method affiliate of FUJI, and hereby announces as follows.

1. Recording of Extraordinary Gains

As a result of the Share Transfer, FUJI expects to record a gain on sale of investment securities of 8,189 million yen (extraordinary income) in the consolidated financial results for the fourth quarter of the fiscal year ending February 2026, and a gain on sale of affiliated company shares of 17,447 million yen (extraordinary income) in the individual financial results.

2. Earnings Forecast

The impact of the Share Transfer on FUJI’s earnings has been reflected in the “Consolidated Earnings Forecast for the Fiscal Year Ending February 2026” as stated in the “Summary of Financial Results for the Third Quarter of the Fiscal Year Ending February 2026 [Japanese GAAP] (Consolidated)” disclosed today.